<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00032006</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-N0052</org_study_id>
    <secondary_id>CDR0000069248</secondary_id>
    <nct_id>NCT00032006</nct_id>
  </id_info>
  <brief_title>Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer</brief_title>
  <official_title>A Trial Of Neoadjuvant Androgen Supression And Dose Escalation Transperineal Ultrasound-Guided Brachytherapy For Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as&#xD;
      goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing&#xD;
      androgens. Internal radiation uses radioactive material placed directly into or near a tumor&#xD;
      to kill tumor cells. Combining hormone therapy with internal radiation may be effective in&#xD;
      treating locally recurrent prostate cancer.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of hormone therapy followed by internal&#xD;
      radiation in treating patients who have locally recurrent prostate cancer following&#xD;
      external-beam radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the nature, intensity, and time course of health-related quality of life&#xD;
           changes in patients with locally recurrent prostate adenocarcinoma treated with androgen&#xD;
           suppression and transperineal ultrasound-guided brachytherapy after external beam&#xD;
           radiotherapy.&#xD;
&#xD;
        -  Determine the morbidity of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the overall survival, disease-free survival, and disease-specific survival of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the clinical patterns of tumor recurrence (i.e., time to local tumor&#xD;
           progression or distant failure) and time to biochemical failure of patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the post-brachytherapy dosimetric coverage of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive androgen suppression comprising goserelin subcutaneously (as either 4&#xD;
      one-month depot injections or 1 one-month depot injection and 1 three-month depot injection)&#xD;
      OR leuprolide intramuscularly (as 4 one-month depot injections or 1 one-month depot injection&#xD;
      and 1 three-month depot injection or 1 four-month depot injection) AND oral flutamide 3 times&#xD;
      daily for 112 days OR oral bicalutamide once daily for 112 days.&#xD;
&#xD;
      Within 4 weeks after completion of androgen suppression, patients are sequentially enrolled&#xD;
      to 2 different cohorts of brachytherapy.&#xD;
&#xD;
        -  Cohort 1: Patients undergo initial-dose transperineal interstitial permanent prostate&#xD;
           brachytherapy with iodine I 125 or palladium Pd 103.&#xD;
&#xD;
        -  Cohort 2: After a minimum of 1-year follow-up for all patients in cohort 1, if tolerance&#xD;
           is acceptable, additional patients undergo higher-dose transperineal interstitial&#xD;
           permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.&#xD;
&#xD;
      Quality of life is assessed at baseline, within 2 weeks prior to brachytherapy, every 3&#xD;
      months for 1 year, and then every 6 months for 2 years.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then&#xD;
      annually for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 83-166 patients (83 per cohort) will be accrued for this study&#xD;
      within 1.5-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quality of life</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor recurrence</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>brachytherapy + radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 4 weeks after completion of androgen suppression, patients are sequentially enrolled to 2 different cohorts of brachytherapy.&#xD;
Cohort 1: Patients undergo initial-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.&#xD;
Cohort 2: After a minimum of 1-year follow-up for all patients in cohort 1, if tolerance is acceptable, additional patients undergo higher-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.&#xD;
Quality of life is assessed at baseline, within 2 weeks prior to brachytherapy, every 3 months for 1 year, and then every 6 months for 2 years.&#xD;
Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <arm_group_label>brachytherapy + radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>brachytherapy + radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed locally recurrent or persistent prostate adenocarcinoma&#xD;
&#xD;
               -  Locally recurrent disease&#xD;
&#xD;
               -  Prostate-specific antigen (PSA) no greater than 10 ng/mL&#xD;
&#xD;
               -  N0 and M0 (at time of initial diagnosis and at time of local recurrence)&#xD;
&#xD;
                    -  Lymph nodes must be negative or will be negative after nodal sampling or&#xD;
                       dissection&#xD;
&#xD;
          -  More than 18 months after completion of prior external beam radiotherapy&#xD;
&#xD;
          -  Must have had 1 of the following disease characteristics prior to external beam&#xD;
             radiotherapy:&#xD;
&#xD;
               -  T1-2a, Gleason score 2-6, and PSA no greater than 15 ng/mL&#xD;
&#xD;
               -  T1-2a, Gleason score 7, and PSA no greater than 4 ng/mL&#xD;
&#xD;
               -  T2b, Gleason score 2-6, and PSA no greater than 6 ng/mL&#xD;
&#xD;
          -  Must have American Urological Association Symptom Index score no greater than 15&#xD;
&#xD;
          -  Transrectal ultrasound-determined prostate planimetry volume no greater than 60 mL&#xD;
&#xD;
          -  No pubic arch interference of more than 1/3 the prostatic volume determined by&#xD;
             transrectal ultrasound or pelvic CT scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-1 OR&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 5 years&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No persistent late intestinal or bladder toxicity grade 2 or greater&#xD;
&#xD;
          -  No other major medical or psychiatric illness that would preclude study&#xD;
&#xD;
          -  No metallic hip prosthesis&#xD;
&#xD;
          -  No other malignancy within the past 5 years except localized basal cell or squamous&#xD;
             cell skin cancer&#xD;
&#xD;
          -  No other concurrent illness that would limit life expectancy&#xD;
&#xD;
          -  Suitable for spinal or general anesthesia&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for prostate cancer&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 12 months since prior androgen suppression except goserelin or leuprolide&#xD;
             with flutamide or bicalutamide begun within the past 30 days&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior external beam radiotherapy doses exceeding 71 Gy to the prostate&#xD;
&#xD;
          -  No prior radionuclide prostate brachytherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior transurethral prostate resection&#xD;
&#xD;
          -  No prior prostatectomy or prostatic cryosurgery&#xD;
&#xD;
          -  No prior bilateral orchiectomy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent participation in another medical research study for prostate cancer&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M. Pisansky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Scottsdale Oncology Program</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212-4772</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Vincent Hospital Cancer Center, Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

